Press releases
- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
- RemeGen Presents Oral Presentation on Evaluation of Its Proprietary Disitamab Vedotin (RC48) for Cervical Cancer at ESGO 2024
Key statistics
On Friday, RemeGen Co Ltd (REG:FRA) closed at 3.10, 66.67% above the 52 week low of 1.86 set on Feb 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.10 |
---|---|
High | 3.10 |
Low | 3.10 |
Bid | 2.84 |
Offer | 3.14 |
Previous close | 3.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 22.13bn HKD |
EPS (TTM) | -3.03 HKD |
Data delayed at least 15 minutes, as of May 31 2024 07:01 BST.
More ▼